title: Cytoprotective agents used in the treatment of patients with cancer.
abstract: OBJECTIVE
  To provide a review of the literature of commonly prescribed cytoprotective agents used in the treatment of patients with cancer.
  
  
  METHODS
  Journal articles, research reports, review articles, and web sites.
  
  
  CONCLUSIONS
  Multiple agents have been theorized to have cytoprotective properties. Significant evidence exists supporting the use of some cytoprotective agents approved by the US Food and Drug Administration (FDA). More research is needed to determine the efficacy of new cytoprotective agents and expanded indications for those agents currently used.
  
  
  CONCLUSIONS
  Knowledge of the indications for and side effect profiles of cytoprotective agents is a necessary component of oncology nursing care. Familiarity with evidence-based research that supports or refutes the use of FDA-approved cytoprotective agents or alternative agents is helpful when suggesting, prescribing, or administering such agents.
authors: UPMC Passavant Cancer Center, Pittsburgh, PA, USA. Hoglewp@ph.upmc.edu
authors: William P
authors: WP
authors: Hogle
mesh_terms: D004999:Amifostine / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D019610:Cytoprotection; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D005973:Glutamine / Q000627:therapeutic use*; D006801:Humans; D015080:Mesna / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000451:nursing / Q000473:pathology; D011929:Razoxane / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D005973:Glutamine; D011929:Razoxane; D005346:Fibroblast Growth Factors; D004999:Amifostine; D015080:Mesna